Our collaborative work with the Tan Group at UC Davis on constructing cyborg bacteria by intracellular hydrogelation is accepted for publication in Advanced Science.
Our groups work on gelated cell-based stem cell expansion substrate is accepted for publication in Advanced Healthcare Materials.
Congratulations to Jerry Tsai for receiving the 2022 Merck Young Scientist Award in Poster Competition on his work in antibacterial drug delivery! [news]
Our group's collaborative work with King's College on a membrane-lytic peptide based anticancer nanotherapeutic is accepted for publication in Advanced Science. [news]
Congratulations to Dr. Hu on receiving the 2021 Academia Sinica Early-Career Investigator Research Achievement Award.
Congratulations to Chung-Yao Hsu and Max Shiau on winning the poster competition at the 2021 IBMS Research Day.
Our lab's work on gelated dendritic cells for adoptive anticancer T cell therapy is featured as inside cover on Advanced Materials.
Congratulations to Chung-Yao Hsu for passing his qualifying exam.
Our group's research on adopting gelated dendritic cells for enhancing anticancer immunotherapy is accepted for publication by Advanced Materials.
Our group's review article on antiviral nanomedicine for pandemic control is accepted for publication by Drug Delivery and Translational Research.
Our group's collaborative work with NTUH on a nanoparticle Trm vaccine for universal influenza vaccination is accepted for publication in Molecular Therapy - Methods and Clinical Development.
Che-Ming Jack Hu (胡哲銘）
Associate Research Fellow
Institute of Biomedical Sciences, Academia Sinica
Dr. Jack Hu recevied his Ph.D. in Biomedical Engineering from the University of California, San Diego in 2011 and recevied postdoctoral trainings in the Nanoengineering Department of UCSD. He holds a B.S. degree in Biomedical Engineering with minors in Mechanical Engineering and Electrical Engineering from UC Berkeley.
Nanotechnology in medicine has shown tremendous value in drug delivery and vaccine preparations, where pharmacokinetics and immune activation can be finely tuned via rational nanomaterials engineering. The research focus of the laboratory is to develop novel therapeutic nanomaterials with an emphasis toward clinical translation. We seek to adopt an engineering approach to improve treatments for major diseases including cardiovascular disease, cancer, and infectious disease.